Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL402118 | 0.87 | RAB9A (0.50) | HDAC3ALDH1A1TDP1NPC1RAB9A | |
| SCHEMBL11981560 | 0.83 | HDAC3 (0.57) | HDAC3MAPK8ALDH1A1TDP1NPC1 | |
| SCHEMBL401126 | 0.81 | LMNA (0.54) | HDAC3ALDH1A1MCHR1NPC1RAB9A | |
| SCHEMBL1096805 | 0.79 | MEN1 (0.46) | ALDH1A1TDP1MCHR1NPC1RAB9A | |
| SCHEMBL404268 | 0.77 | DRD2 (0.46) | HDAC3DRD2DRD4DRD3MAPK8 | |
| SCHEMBL12141627 | 0.75 | TSHR (0.64) | HDAC3ALDH1A1TDP1NPC1RAB9A | |
| SCHEMBL404814 | 0.74 | MEN1 (0.40) | DRD2DRD4DRD3ALDH1A1TDP1 | |
| SCHEMBL404935 | 0.74 | PLK1 (0.54) | HDAC3DRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL14159023 | 0.73 | CYP1A2 (0.63) | MAPK8ALDH1A1NPC1RAB9A | |
| SCHEMBL16492521 | 0.72 | DRD2 (0.64) | HDAC3DRD2DRD4DRD3MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | HDAC3 2114/4885DRD2 3836/4885DRD4 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.